OTC:CVALF

Compassionate Care Solutions Provider Covalon Participating in the Canadian Vascular Access Association and World Congress on Vascular Access Joint Conference on April 26-28, 2023 in Toronto

Retrieved on: 
Wednesday, April 26, 2023
Learning, CVAA, Senior, CLABSI, Research, Sheraton Centre Toronto Hotel, Science, Patient, Vascular access, Fluid mechanics, FDA, Health, Global marketing, Conference, Pharmaceutical industry, Medical device

CVAA is the only Canadian national conference that brings together infusion therapy and vascular access professionals in Canada.

Key Points: 
  • CVAA is the only Canadian national conference that brings together infusion therapy and vascular access professionals in Canada.
  • WoCoVA aims to improve vascular access for patients worldwide by promoting the science and practice of vascular access.
  • Visit the Covalon booth to learn more about the company's vascular access and infection prevention solutions, and how Covalon is focused on compassionate care tech that benefits both patients and care providers.
  • IV Clear ® - the world's only dual-antimicrobial vascular access dressing that offers complete transparency at and around the insertion site for easy daily assessment.

Covalon Presents New CLABSI Conscious Series Webinar: Protecting CVADs from Gross Contamination

Retrieved on: 
Monday, March 27, 2023
Learning, MSN, NICU, COVID-19, CLABSI, Centers for Disease Control and Prevention, CDC, Patient, Hyper-CVAD, Climate, Bacteria, Death, PICU, Safety, Pharmaceutical industry

MISSISSAUGA, ON, March 27, 2023 /PRNewswire/ - Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV) (OTCQX: CVALF), an advanced medical technologies company, today announced the second expert-led webinar in its CLABSI Conscious campaign, titled "Protecting CVADs from Gross Contamination", to be held on Wednesday, March 29 at 1pm EDT.

Key Points: 
  • MISSISSAUGA, ON, March 27, 2023 /PRNewswire/ - Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV) (OTCQX: CVALF), an advanced medical technologies company, today announced the second expert-led webinar in its CLABSI Conscious campaign, titled "Protecting CVADs from Gross Contamination", to be held on Wednesday, March 29 at 1pm EDT.
  • Central line-associated blood stream infections ("CLABSI") often result from fluids and other substances that contain bacteria and which end up in contact with a central venous access device ("CVAD").
  • The CDC (Centers for Disease Control and Prevention) has reported a 47% increase in CLABSIs since the outset of the COVID-19 pandemic.
  • Webinar attendees will hear expert opinions related to CLABSI conscious practices, and explore new technology designed to help prevent CLABSIs by maintaining safety and consistency in the NICU, PICU, and beyond.

Leader in Compassionate Care Infection Prevention Solutions, Covalon, to Participate in the Synova NICU Leadership Forum 2023 in Tucson, Arizona from March 19 to 23, 2023

Retrieved on: 
Monday, March 20, 2023
Infection, Learning, Senior, Courage, NICU, U.S. News & World Report, Synova, Hospital, Patient, The Company, Fluid mechanics, FDA, Global marketing, Nursing, Medical device, MISSISSAUGA

Visit booth 106 to learn how Covalon is leading the charge with compassion driven innovation through gentler infection prevention solutions.

Key Points: 
  • Visit booth 106 to learn how Covalon is leading the charge with compassion driven innovation through gentler infection prevention solutions.
  • MISSISSAUGA, ON, March 20, 2023 /PRNewswire/ - Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV) (OTCQX: CVALF), an advanced medical technologies company, today announced its participation in the Synova NICU Leadership Forum from Sunday, March 19 to Thursday, March 23, 2023 in Tuscon, Arizona.
  • "We're excited to be attending Synova NICU Leadership Forum for the first time so that clinicians and leaders can see, feel, and experience how our compassionate care solutions can help even the tiniest patients."
  • Today, 6 of the top 10 children's hospitals, as ranked by U.S. News & World Report, have adopted Covalon's uniquely designed compassionate care solutions.

Covalon Announces Voting Results from Fiscal 2022 Annual and Special Meeting of Shareholders

Retrieved on: 
Thursday, March 9, 2023
Proxy, AGM, Special, Cryptocurrency, Holding company

MISSISSAUGA, ON, March 9, 2023 /PRNewswire/ - Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV) (OTCQX: CVALF) an advanced medical technologies company, today announced the results of the matters voted upon at its Fiscal 2022 Annual and Special Meeting of Shareholders ("AGM") held March 8, 2023.

Key Points: 
  • MISSISSAUGA, ON, March 9, 2023 /PRNewswire/ - Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV) (OTCQX: CVALF) an advanced medical technologies company, today announced the results of the matters voted upon at its Fiscal 2022 Annual and Special Meeting of Shareholders ("AGM") held March 8, 2023.
  • Shareholders voted in favour of all items of business and each item of business was approved by the requisite number of votes.
  • The matters included the election of the Board of Directors, the appointment of auditors, and the approval of the Company's Omnibus Long-Term Incentive Plan.
  • The voting results are detailed below.

Covalon Welcomes Martin Goldfarb, O.C., to its Board of Directors

Retrieved on: 
Thursday, March 9, 2023
Principal, TSX Venture Exchange, Learning, Marketing, Altamira, University college, Consultant, Workforce, York University, University, Sale, BC Children's Hospital Foundation, Patient, Behavior, TSX, Liberal Party of Canada candidates in the 2004 Canadian federal election, WPP, University of Toronto, Mentorship, Florida State University College of Business, Liberal Party, Management, Security (finance), Anthropology, Infor, Sociology

MISSISSAUGA, ON, March 9, 2023 /PRNewswire/ - Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV) (OTCQX: CVALF) an advanced medical technologies company, today is delighted to announce that Martin Goldfarb has joined its Board of Directors.

Key Points: 
  • MISSISSAUGA, ON, March 9, 2023 /PRNewswire/ - Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV) (OTCQX: CVALF) an advanced medical technologies company, today is delighted to announce that Martin Goldfarb has joined its Board of Directors.
  • Brian Pedlar, Covalon's CEO, said, "I am very pleased to welcome Martin Goldfarb back on Covalon's Board.
  • Martin has been a significant, longstanding shareholder of Covalon, and I look forward to once again benefiting further from his unique insights and experiences."
  • I sincerely believe there is much more that can be achieved by Covalon for patients, healthcare providers, and shareholders alike."

Covalon To Hold Annual and Special Meeting of Shareholders on Wednesday, March 8, 2023

Retrieved on: 
Tuesday, February 28, 2023
Control, Learning, MD, Meeting, Proxy, Bank statement, SEDAR, Password, Security (finance)

Registered shareholders and duly appointed proxyholders will be able to attend, participate, and vote at the Meeting online at https://virtual-meetings.tsxtrust.com/1416 , Meeting ID being 1416, using Password "covalon2023" (case sensitive).

Key Points: 
  • Registered shareholders and duly appointed proxyholders will be able to attend, participate, and vote at the Meeting online at https://virtual-meetings.tsxtrust.com/1416 , Meeting ID being 1416, using Password "covalon2023" (case sensitive).
  • Non-registered shareholders who have not duly appointed themselves as proxyholder will not be able to vote at the Meeting but will be able to attend the Meeting as guests.
  • Guests are invited to attend the meeting by navigating to https://virtual-meetings.tsxtrust.com/1416 , Meeting ID being 1416, and clicking on "I am a Guest".
  • For those interested in learning more about Covalon's solutions, visit www.covalon.com or follow Covalon on LinkedIn , Facebook , Instagram or Twitter .

Covalon Announces Improved First Quarter Fiscal 2023 Results

Retrieved on: 
Thursday, February 23, 2023
Marketing, News, Hospital, Webcast, Investment, Q&A, Patient, Growth, Baozou Big News Events, Geography, Pharmaceutical industry, Cryptocurrency, Film industry

MISSISSAUGA, ON, Feb. 23, 2023 /PRNewswire/ - Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV) (OTCQX: CVALF), an advanced medical technologies company, today announced its first quarter fiscal 2023 results for the period ended December 31, 2022.

Key Points: 
  • MISSISSAUGA, ON, Feb. 23, 2023 /PRNewswire/ - Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV) (OTCQX: CVALF), an advanced medical technologies company, today announced its first quarter fiscal 2023 results for the period ended December 31, 2022.
  • I am pleased to report that revenue for our first quarter of fiscal 2023 increased 25% to $6.2 million.
  • Our sales and marketing teams started fiscal 2023 with a focused sales and marketing strategy, based on the planning and investments we made in 2022.
  • A conference call and webcast to discuss Covalon's Q1 fiscal 2023 financial results will be held Thursday, February 23, 2023 at 9:00am EST.

Infection Prevention Solutions Provider Covalon to Participate for the First Time in NEO - The Conference for Neonatology in Las Vegas, NV on February 22-24, 2023

Retrieved on: 
Monday, February 20, 2023
Life, Christianity in Singapore, Fluid mechanics, Hospital, U.S. News & World Report, Global marketing, Patient, Senior, The Company, Health care, FDA, Infection, Learning, Conference, NEO, Nursing, Medical device, Neonatology, MISSISSAUGA

The NEO conference brings together global experts, healthcare providers, academia, and industry, with a focus on improving the level of care being provided to infants in neonatal intensive care units ("NICUs").

Key Points: 
  • The NEO conference brings together global experts, healthcare providers, academia, and industry, with a focus on improving the level of care being provided to infants in neonatal intensive care units ("NICUs").
  • NEO was designed for participants to better understand and utilize the leading approaches to neonatal intensive care.
  • Major pediatric hospitals have implemented use of Covalon's infection prevention solutions and have gone on to observe improving infection rates."
  • IV Clear ® - the world's only dual-antimicrobial vascular access dressing that offers complete transparency at and around the insertion site for easy daily assessment.

Covalon Announces Conference Call to Discuss First Quarter Fiscal 2023 Financial Results

Retrieved on: 
Friday, February 17, 2023
Bank statement, Q&A, News, SEDAR, Webcast, Baozou Big News Events, Learning, MD

MISSISSAUGA, ON, Feb. 17, 2023 /PRNewswire/ - Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV) (OTCQX: CVALF), an advanced medical technologies company, will release its Q1 Fiscal 2023 financial results on Thursday, February 23, 2023, before markets open.

Key Points: 
  • MISSISSAUGA, ON, Feb. 17, 2023 /PRNewswire/ - Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV) (OTCQX: CVALF), an advanced medical technologies company, will release its Q1 Fiscal 2023 financial results on Thursday, February 23, 2023, before markets open.
  • A conference call and webcast to discuss the financial results will be held on Thursday, February 23, 2023, at 9:00am EST.
  • A recording of the call will be available by calling 1-888-390-0541 or 416-764-8677 and entering the encore replay entry code 219091# until March 9, 2023.
  • For those interested in learning more about Covalon's solutions, visit www.covalon.com or follow Covalon on LinkedIn , Facebook , Instagram or Twitter .

Covalon Announces Fourth Quarter and Year End Results for Fiscal 2022 and Highlights Company Transformation Changes

Retrieved on: 
Thursday, January 26, 2023
EBITDA, Marketing, United Kingdom, Infection, International, Hospital, Government, Pedlar, Growth, Physician, Depreciation, Patient, Intensive care medicine, Investment, Web browser, Cryptocurrency, Nursing, Video game, Pharmaceutical industry

MISSISSAUGA, ON, Jan. 25, 2023 /PRNewswire/ - Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV) (OTCQX: CVALF), an advanced medical technologies company, today announced its fiscal 2022 fourth quarter and year end results for the period ended September 30, 2022.

Key Points: 
  • MISSISSAUGA, ON, Jan. 25, 2023 /PRNewswire/ - Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV) (OTCQX: CVALF), an advanced medical technologies company, today announced its fiscal 2022 fourth quarter and year end results for the period ended September 30, 2022.
  • "Fiscal 2022 was a year of strengthening and transforming our Company," states Brian Pedlar, Covalon President and CEO.
  • A conference call and webcast to discuss Covalon's Fiscal 2022 Year-End Financial Results will be held Thursday, January 26, 2023 at 9:00am EST.
  • The following unaudited table presents Covalon's consolidated statements of operations for the quarters and years ended September 30, 2022 and 2021.